This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contractmanufacturing organization (CMO) to manufacture low-cost insulin. In-house manufacturing the norm.
Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contractmanufacturing organizations (CMOs) that must flexibly handle outsourced production, which can come suddenly and often must quickly be ramped up.
Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. These attributes make some biologic drugs, especially monoclonal antibodies more specific and targeted in their treatment. As a result, some pharmaceutical companies are turning to third parties.
Flush with new business, Philadelphia-based CDMO PCI Pharma Services is blueprinting multiple manufacturing outlays on both sides of the Atlantic. | Altogether, PCI’s manufacturing projects represent an investment of more than $365 million.
In the last year, well-known contractmanufacturing organisations (CMOs) such as Agilent Technologies (Santa Clara, California) and Abzena (Cambridge, UK) have expanded their continuous manufacturing capabilities. US Congress is also making substantial investments to improve the continuous manufacturing of pharmaceuticals.
International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.
Texas has accused Pfizer and manufacturer Tris Pharma of knowingly providing compromised ADHD medicine to a state Medicaid program for children of low-income families. | In its lawsuit, Texas says the companies knew that deficient manufacturing processes compromised the effectiveness of Quillivant XR.
In this last 2022 edition of the series, which started in June , Pharmaceutical Technology is tracking major trial announcements and decisions by regulators and reimbursement agencies that have occurred since mid-October, as well as their potential impact on manufacturing plans. Iomab-B met the durable complete remission endpoint.
Despite China producing a significant proportion of the world’s API supply (mostly small molecule), it manufactures relatively few biosimilar and innovator drugs and no cell and gene therapies for the western markets of Europe and the US despite investments and an increasing number of startups to improve innovative manufacture.
Regulatory decisions have a ripple effect, first affecting the pharma sponsors, and then the companies tasked to manufacture the drug. Pharmaceutical Technology looks at drugs and biologics with recent regulatory verdicts that will likely impact manufacturing volumes. Consequential FDA and EMA decisions.
Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. In April 2023, Forge Biologics received a qualified person (QP) declaration for the manufacture of AAV gene therapies at its facility in Columbus, Ohio, US.
Crossing the approval hurdle for a new drug is a big milestone for pharmaceutical companies. However, efficiently manufacturing the drug represents another barrier to cross before realizing the full revenue potential then successfully. GlobalData is the parent company of Pharmaceutical Technology. Regulatory decisions come in.
Symbiosis Pharmaceutical Services Ltd (Symbiosis), a fast-growing contractmanufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and biopharmaceuticals including Advanced Therapeutical Medicinal Products (ATMPs), has announced the completion of a £1.3
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. The drug was approved to treat type 2 diabetes mellitus in May. million in Q3.
In such turbulent times, ensuring the most efficient and cost-effective manufacturing frameworks becomes even more important. Most pharmaceutical and biotech companies outsource certain production tasks to contractmanufacturing organizations (CMOs). SK Biotek is contracted to manufacture the small molecule API.
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. The drug was approved to treat type 2 diabetes mellitus in May. million in Q3.
The success of COVID-19 vaccines paved the path for mRNA-based drug products. However, synthesis and manufacturing of mRNA is fraught with several challenges as the production of such biomolecules is complex, cost intensive, requires specialized expertise and dedicated equipment.
Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.
Biosimilars have been transforming the pharmaceutical landscape by offering cost-effective alternatives to biologic drugs. As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies.
Pharmaceutical solid dose manufacturing companies in contract marketing segment have gained a vital position in pharmaceutical formulations. Pharmaceutical solid dosage forms are the most popular in the pharmaceutical industry and are one of the most used drug delivery methods across patient groups.
Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Pfizer will provide contractmanufacturing services at its facility in McPherson, Kansas, to supply the drug to Gilead.
The global pharma industry experienced a 9% rise in social media posts on orphan designated drugs in Q1 2023 compared with the previous quarter, with the highest share accounted for Teva Pharmaceutical Industries, according to GlobalData’s analysis of social media posts.
In order to get a therapy to the market, pharma companies often outsource the drugmanufacturing to specialist contractmanufacturing organizations (CMOs). While Catalent Inc and PCI Pharma Services are in charge of the solid dose and packaging of Lupkynis, Lonza is manufacturing the small molecule API.
The global pharmaceutical industry experienced an 18% drop in company filings mentions of orphan designated drugs in Q1 2023 compared with the previous quarter, with the highest share accounted for by Horizon Therapeutics with 50% year-on-year increase, according to GlobalData’s analysis of over 182 pharmaceutical company filings.
Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. As a result, biopharmaceutical contractmanufacturing has picked up pace in the recent years. What are the Benefits of Outsourcing Biopharmaceutical Manufacturing?
Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. As a result, biopharmaceutical contractmanufacturing has picked up pace in the recent years. What are the Benefits of Outsourcing Biopharmaceutical Manufacturing?
A leader from ACG Engineering shares insight on how âsmartâ drugmanufacturing, accelerated by COVID-19, can best be put to work now and in months to come.
4th Edition Market Study into Small Molecule Drug Product ContractManufacturer Quality – ResearchAndMarkets.com 4th Edition Market Study into Small Molecule Drug Product ContractManufacturer Quality – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Small Molecule Drug Product ContractManufacturer Quality Benchmarking (..)
Although biopharmaceuticals offer significant profit margins and have demonstrated the potential to treat a myriad of disease indications, they are generally associated with high costs of development and complex manufacturing protocols. Advanced and complex technologies are required for manufacturing, as well as testing of biopharmaceuticals.
The FDA approved fewer innovative drugs, New Molecular Entities (NMEs), in 2022 than it did in 2021: only 42 drugs compared to 59 drugs. In 2023, there will be opportunities for a wider range of CMOs that can offer services for less innovative drugs requiring reformulation or biosimilar production.
In preparation for this, drugmanufacturing will begin later this year and will be outsourced to external contractmanufacturing organisations (CMOs). The most common marketed drugs in this space aim to address the hyperammonaemia caused by the defective genes in this disorder.
The current landscape consists of more than 95 players that claim to offer oligonucleotide contractmanufacturing services for research, diagnostic and therapeutic applications. These contract service providers are actively entering into strategic collaborations to augment their existing portfolios. Our Social Media Platform.
The overall manufacturing of oligonucleotides involves the following steps. Owing to the incessant demand for oligonucleotide-based products, several small to mid-sized companies and certain pharma giants, have begun outsourcing their manufacturing operations to contract service providers. Accelerating Oligonucleotide Demand.
Under the agreement, Aurena Laboratories will establish a production unit to meet the regulatory requirements for the manufacture of Lipidor’s pharmaceutical products. This is an important step towards a licensing agreement for Lipidor drug candidates, AKP01 and AKP02, for the treatment of psoriasis.
Amid a corporate review of AstraZeneca’s global manufacturing and supply network, the company’s Indian subsidiary is planning to close up shop at the “beating heart” of its India operations in Bang | AstraZeneca Pharma India will exit its production plant in Bangalore, India, “in due course,” the company said in a filing.
Global Pharmaceutical ContractManufacturing Market 2021-2026: Increasing Focus on Specialty Drugs and Attractive Nuclear Medicine Sector – ResearchAndMarkets.com Global Pharmaceutical ContractManufacturing Market 2021-2026: Increasing Focus on Specialty Drugs and Attractive Nuclear Medicine Sector – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)
WuXi Vaccines launched its first standalone vaccine contractmanufacturing facility in Suzhou. With the plant, the company adds drug substance and drug product capacity for projects in various stages of development.
Large (market cap $10–100bn) and mega-cap (market cap >$100bn) sponsors also require contractmanufacturers and packagers with specialist injectable capabilities in the case of cell and gene therapies, as shown in the report titled Contract Injectable Packaging Trends in the Bio/Pharma Industry (August 2022).
A radioactive tracer is a drug that is composed of a short-lived medical isotope tightly attached to a carrier molecule. Before being accessible for routine clinical use, the radioactive tracer must demonstrate its harmlessness in the patients body, along with its benefit for the treatment purpose (similar to any classical drug).
After laying out a goal to launch four new drugs in 2023, Eli Lilly has run into yet another regulatory snag. | The FDA has rejected Lilly’s investigational atopic dermatitis treatment lebrikizumab over findings uncovered during the inspection of a third-party contractmanufacturing organization.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content